Home / Tag / Pharma Sector

Posts tagged as:

Pharma Sector

Sun Pharma net profit more than doubles up to Rs 322.63 crore for Q1

by admin on July 29, 2010

in Company Annoucements

Sun Pharmaceutical Industries has announced the unaudited results for the quarter ended June 30, 2010. The Company has posted a surge of 165.51% in net profit after tax of Rs 322.63 crore for the quarter ended June 30, 2010 as compared to Rs 121.51 crore for the quarter ended June 30, 2009. Total Income has [...]

Tagged as: ,

{ 0 comments }

Cadila Healthcare –Buy- Sharekhan

by free stock tips on July 5, 2010

in Stock-News

Cadila Healthcare (Cadila)’s recent Para IV filing of Lialda could lead to an incremental earnings per share (EPS) of Rs6-7 upon the launch (patent expiry in 2020) whereas the recently-approved Anastrazole (a breast cancer drug with shared exclusivity) would fetch in a decent Rs2-3 for the same. We think the market is yet to factor [...]

Tagged as: , , ,

{ 0 comments }

Venus Remedies rises on receiving patent for Potentox in New Zealand

by free stock tips Stock-News

Venus Remedies has entered into the Australasia region by receiving a patent from Commissioner of Patents, Trademarks and Design, Intellectual Property office of New Zealand for its antibiotic Potentox, a fixed dose combination of cefepime and amikacin. The scrip is currently trading at Rs. 270.00, up by 5.90 points or 2.23% from its previous closing [...]

Tagged as: ,

Read the full article →

Sun Pharma –Buy- Sharekhan

by free stock tips Broker tips

Sun Pharmaceuticals (Sun) has announced patent settlement with Orion Corporation (Orion) for the generic version of Stalevo ($120 million revenue) and Comtan ($90 million revenue), which are used in the treatment of Parkinson’s disease. Under the terms of the settlement, Sun will be able to launch the generic version of Stalevo (for strength of 25/100/200mg [...]

Tagged as: , , ,

Read the full article →

Sun Pharma’s US outlook improves

by admin Stock-News

Sun Pharma received just one approval from the US Food and Drug Administration (FDA) to market a generic drug In the January-March quarter, Sun Pharmaceutical Industries Ltd received just one approval from the US Food and Drug Administration (FDA) to market a generic drug. In contrast, approvals seem to be pouring in during the current [...]

Tagged as: ,

Read the full article →

Parabolic Drugs IPO Analysis, Updates, Company Profile, Risk and Concern Outlook

by free stock tips IPO

Parabolic Drugs IPO: Parabolic Drugs Limited is coming up with a 100% book building; initial public offering (IPO) of 20,25,702 shares to raise about Rs 200 crore. The equity shares of Rs 10 each are being offered in a price band of Rs 75-85 per equity share. At least 50% of the issue will be [...]

Tagged as: , ,

Read the full article →

Abbott acquires Piramal’s Healthcare Solutions business

by free stock tips Stock-News

Abbott India has acquired Piramal’s Healthcare Solutions business (Domestic Formulations) for an up-front payment of USD2.12 billion and an additional USD400 million annually for the next four years. The acquisition will accelerate Abbott’s emerging markets growth following the recent acquisition of Solvay Pharmaceuticals and announcements last week of Abbott’s collaboration with Zydus Cadila. “This strategic [...]

Tagged as: , ,

Read the full article →

Medium term view – Divis Laboratories Limited : IDBI Capital

by free stock tips Medium Term

Divis Laboratories Limited, an Active Pharma Ingredients (APIs) & Intermediates company, was incorporated in the year 1990. Divis prime fundamental is Research & Development and focuses on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company provides complete turnkey solutions to the domestic Indian pharmaceutical industry. The overall trend [...]

Tagged as: , , , ,

Read the full article →

Aventis Pharma – Neutral- Motilal Oswal

by free stock tips Stock-News

We attended Aventis Pharma – APL’s recent annual general meeting (AGM). The management indicated that its focus will be on the domestic formulations business, with rural and OTC segments as the key growth drivers. APL is likely to incur some extra expenditure for establishing its presence in these segments. In CY09, APL launched 15 new [...]

Tagged as: , , ,

Read the full article →

Aventis Pharma –Reduce- Angel Securities

by free stock tips Broker tips

Aventis Pharma (Aventis) announced its 1QCY2010 results which were below our expectation. Net Sales came in at Rs251.4 crore up 9.8% driven by domestic sales, which grew by 11.1% to Rs197.2cr (Rs 177.5cr) (excluding Rabipur, domestic sales growth came in at 21.7%); however, export sales de-grew by 5.9% to Rs54.2 crore. On the Operating front, [...]

Tagged as: , , ,

Read the full article →